

# Anti-GUCY2C Reference Antibody (indusatumab vedotin)

Recombinant Antibody

Catalog # APR10435

## Product Information

---

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">P25092</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	123403

## Additional Information

---

Target/Specificity	GUCY2C
Endotoxin Conjugation	MMAE
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


## Protein Information

---


Name	GUCY2C {ECO:0000303   PubMed:22521417, ECO:0000312   HGNC:HGNC:4688}
Function	Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP (PubMed: <a href="#">11950846</a> , PubMed: <a href="#">1718270</a> , PubMed: <a href="#">22436048</a> , PubMed: <a href="#">22521417</a> , PubMed: <a href="#">23269669</a> ). Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C (PubMed: <a href="#">1680854</a> , PubMed: <a href="#">1718270</a> ). Also activated by the endogenous peptides guanylin and uroguanylin (PubMed: <a href="#">8381596</a> ).
Cellular Location	Cell membrane; Single-pass type I membrane protein Endoplasmic reticulum membrane; Single- pass type I membrane protein. Note=The 145 kDa plasma membrane form of GUCY2C contains sialic acid and galactose residues, while a differentially glycosylated 130 Kda form is a high mannose form that is resident in the endoplasmic reticulum and may serve as the precursor for the cell surface form

## Images

---



Anti-GUCY2C Reference Antibody (indusatumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-GUCY2C Reference Antibody (indusatumab vedotin) is more than 95% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.